JW Holdings Past Earnings Performance
Past criteria checks 1/6
JW Holdings has been growing earnings at an average annual rate of 59.6%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 5.2% per year. JW Holdings's return on equity is 8.9%, and it has net margins of 2.1%.
Key information
59.6%
Earnings growth rate
59.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 5.2% |
| Return on equity | 8.9% |
| Net Margin | 2.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
JW Holdings' (KRX:096760) Soft Earnings Are Actually Better Than They Appear
Mar 25
Shareholders Can Be Confident That JW Holdings' (KRX:096760) Earnings Are High Quality
Apr 01Recent updates
JW Holdings' (KRX:096760) Soft Earnings Are Actually Better Than They Appear
Mar 25Shareholders Can Be Confident That JW Holdings' (KRX:096760) Earnings Are High Quality
Apr 01Would Shareholders Who Purchased JW Holdings' (KRX:096760) Stock Three Years Be Happy With The Share price Today?
Mar 15Is JW Holdings (KRX:096760) Using Too Much Debt?
Feb 15What Type Of Shareholders Make Up JW Holdings Corporation's (KRX:096760) Share Registry?
Jan 20
Do These 3 Checks Before Buying JW Holdings Corporation (KRX:096760) For Its Upcoming Dividend
Dec 24Read This Before Buying JW Holdings Corporation (KRX:096760) For Its Dividend
Dec 06Revenue & Expenses BreakdownBeta
How JW Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 928,072 | 19,026 | 249,623 | 33,734 |
| 30 Sep 23 | 907,455 | 13,382 | 244,364 | 31,870 |
| 30 Jun 23 | 908,428 | 19,612 | 245,777 | 35,309 |
| 31 Mar 23 | 880,029 | 33,135 | 233,154 | 33,262 |
| 31 Dec 22 | 864,536 | 22,152 | 240,614 | 33,148 |
| 30 Sep 22 | 854,988 | 3,861 | 256,615 | 27,046 |
| 30 Jun 22 | 815,391 | -497 | 246,031 | 18,944 |
| 31 Mar 22 | 800,272 | -2,781 | 249,682 | 18,410 |
| 31 Dec 21 | 788,937 | -2,778 | 249,160 | 17,760 |
| 30 Sep 21 | 758,792 | 21,163 | 241,108 | 18,179 |
| 30 Jun 21 | 780,914 | 17,459 | 242,388 | 22,165 |
| 31 Mar 21 | 783,856 | 17,527 | 230,789 | 22,793 |
| 31 Dec 20 | 781,515 | 9,064 | 229,010 | 23,127 |
| 30 Sep 20 | 753,452 | -24,454 | 233,066 | 21,226 |
| 30 Jun 20 | 743,994 | -23,576 | 235,392 | 21,783 |
| 31 Mar 20 | 737,324 | -22,655 | 237,921 | 23,238 |
| 31 Dec 19 | 728,082 | -28,676 | 242,480 | 22,402 |
| 30 Sep 19 | 728,869 | -7,507 | 241,821 | 21,397 |
| 30 Jun 19 | 732,685 | -26,022 | 247,061 | 20,239 |
| 31 Mar 19 | 722,599 | -26,837 | 250,341 | 17,028 |
| 31 Dec 18 | 725,382 | -20,090 | 248,779 | 17,899 |
| 30 Sep 18 | 695,347 | -27,907 | 238,674 | 18,520 |
| 30 Jun 18 | 681,053 | -12,269 | 229,549 | 20,418 |
| 31 Mar 18 | 678,729 | -6,907 | 225,799 | 23,125 |
| 31 Dec 17 | 681,164 | 55,659 | 219,492 | 24,018 |
| 30 Sep 17 | 697,519 | 57,333 | 218,666 | 23,373 |
| 30 Jun 17 | 692,696 | 62,488 | 219,234 | 23,090 |
| 31 Mar 17 | 696,450 | 52,590 | 211,072 | 20,869 |
| 31 Dec 16 | 684,839 | -8,663 | 207,974 | 20,458 |
| 30 Sep 16 | 679,680 | -3,037 | 204,286 | 20,056 |
| 30 Jun 16 | 665,117 | -7,153 | 203,826 | 19,610 |
| 31 Mar 16 | 648,584 | 537 | 200,436 | 19,601 |
| 31 Dec 15 | 622,825 | 181 | 194,269 | 18,591 |
| 30 Sep 15 | 632,128 | -3,036 | 206,120 | 18,831 |
| 30 Jun 15 | 612,284 | -2,747 | 197,640 | 18,804 |
| 31 Mar 15 | 593,142 | -7,121 | 192,147 | 19,670 |
| 31 Dec 14 | 573,935 | -10,940 | 187,814 | 20,056 |
| 30 Sep 14 | 538,822 | -9,883 | 171,347 | 19,723 |
| 30 Jun 14 | 531,509 | -14,600 | 169,824 | 18,624 |
| 31 Mar 14 | 527,415 | 16,797 | 172,153 | 17,435 |
| 31 Dec 13 | 530,263 | 17,817 | 173,982 | 16,301 |
| 30 Sep 13 | 545,829 | 8,276 | 185,226 | 15,133 |
| 30 Jun 13 | 546,155 | 8,282 | 183,866 | 15,718 |
Quality Earnings: A096760 has a large one-off loss of ₩41.2B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A096760's current net profit margins (2.1%) are lower than last year (2.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A096760 has become profitable over the past 5 years, growing earnings by 59.6% per year.
Accelerating Growth: A096760's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A096760 had negative earnings growth (-14.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (36.1%).
Return on Equity
High ROE: A096760's Return on Equity (8.9%) is considered low.